Lu, Chunwan http://orcid.org/0000-0002-3823-9434
Yang, Dafeng
Klement, John D. http://orcid.org/0000-0003-4334-4076
Colson, Yolonda L.
Oberlies, Nicholas H. http://orcid.org/0000-0002-0354-8464
Pearce, Cedric J. http://orcid.org/0000-0002-0212-1127
Colby, Aaron H.
Grinstaff, Mark W. http://orcid.org/0000-0002-5453-3668
Liu, Zhuoqi
Shi, Huidong http://orcid.org/0000-0003-1137-3390
Ding, Han-Fei
Liu, Kebin http://orcid.org/0000-0003-1965-7240
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA133085, CA236436, CA125066, CA227433)
U.S. Department of Veterans Affairs (CX001364)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 21 September 2021
Revised: 11 March 2022
Accepted: 16 March 2022
First Online: 30 March 2022
Competing interests
: AHC, MWG, and NHO have ownership interest in Ionic Pharmaceuticals, LLC. KL has an ownership interest in CheMedImmune Inc. NHO is a member of the Scientific Advisory Board of Mycosynthetix, Inc. CJP has an ownership interest in Mycosynthetix, Inc. Other authors have declared that no conflict of interest exists.